Rakuten Investment Management Inc. Raises Holdings in IDEXX Laboratories, Inc. $IDXX

Rakuten Investment Management Inc. boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 692.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,821 shares of the company’s stock after acquiring an additional 12,950 shares during the quarter. Rakuten Investment Management Inc.’s holdings in IDEXX Laboratories were worth $10,195,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories in the 4th quarter worth approximately $29,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after buying an additional 20 shares during the period. Wormser Freres Gestion lifted its holdings in IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after buying an additional 47 shares during the period. Finally, WealthCollab LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth approximately $30,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on IDXX shares. UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Citigroup started coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Stock Up 0.5%

IDEXX Laboratories stock opened at $573.00 on Wednesday. The firm has a market cap of $45.20 billion, a price-to-earnings ratio of 42.19, a PEG ratio of 3.12 and a beta of 1.55. The stock has a fifty day simple moving average of $563.14 and a two-hundred day simple moving average of $624.14. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.